About Intercept Pharmaceuticals
Intercept Pharmaceuticals is a Healthcare company based in New York (United States) founded in 2002 by Mark Pruzanski, and was acquired by Alfasigma in September 2023. Intercept Pharmaceuticals has raised $121 million across 5 funding rounds from investors including Orbimed, Alfasigma and Genextra. The company has 341 employees. Intercept Pharmaceuticals offers products and services including FXR Agonist. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its legal entity is Intercept Pharmaceuticals, Inc. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.
Company details
Developer of therapeutics to treat progressive non-viral liver diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic liver diseases such as Nonalcoholic steatohepatitis (NASH), and Primary sclerosing cholangitis. FXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue. FXR regulates a wide variety of target genes critically involved in the control of BA synthesis and transport, Lipid metabolism, and Glucose homeostasis.
- Headquarters New York, United States
- Employees 341
- Founders Mark Pruzanski
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website interceptpharma.com
- Social LinkedIn X
- Acquired by Alfasigma (Sep 2023)
- Legal Name Intercept Pharmaceuticals, Inc.
Products & Services of Intercept Pharmaceuticals
Intercept Pharmaceuticals offers a comprehensive portfolio of products and services, including FXR Agonist.
Treatment for primary biliary cholangitis liver disease
Funding Insights of Intercept Pharmaceuticals
Intercept Pharmaceuticals has successfully raised a total of $121M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $500 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $121M
- Total Rounds 5
- Last Round Post-IPO — $500M
- First Round $41M
(May 2006)
- Investors Count 4
All 5 funding rounds of Intercept Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
5 investors in total: 5 institutional.
Investors in Intercept Pharmaceuticals
Intercept Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Alfasigma and Genextra.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
A holding company focused on life science investments is operated. | genextra.it | Milan, Italy | ||
Manages investments and risks to deliver consistent returns for institutional investors. | 2001 | bamfunds.com | Chicago, United States | |
Buyouts are targeted through venture capital and private equity investments. | jafco.co.jp | Minato City, Japan | ||
Generic tablets, capsules, syrups, and injectables are manufactured. | 2015 | alfasigma.com | Bologna, Italy |
Investor details for Intercept Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Intercept Pharmaceuticals
189 people are tracked at Intercept Pharmaceuticals (104 in leadership, 6 in board & advisors, 79 in team); the tracked headcount is 341.
| Name | Role | Group |
|---|---|---|
Mark Pruzanski | Founder | Leadership |
Anne Chiplin | Senior Director, Safety Evaluation And Risk Management | Leadership |
Amarita S Randhawa Pharmd | Executive Medical Director - Nash, Medical Affairs | Leadership |
Mary Erickson | Vice President Clinical Research Translational Medicine | Leadership |
Jaimee Reid Jd, Llm | Head Of Legal Compliance And Privacy Officer | Leadership |
Caroline Fajolle | Executive Director, Human Resources - Commercial And Quality & Tech Ops | Leadership |
Veruska di Sena | SVP - Head Of US Medical Affairs | Leadership |
Gina Arrigo Wilson | Associate Director Of Key Accounts | Leadership |
David Swift | Executive Director, Market Access Strategic Accounts | Leadership |
Kimberly Jones | Associate Director, Training U.s. Commercial | Leadership |
Sangeeta Sawhney M.D. | Svp, Head Research And Development | Leadership |
Richard Johnson | Senior Vice President Head Of Human Resources | Leadership |
Rosa Rodriguez | Senior Manager - Office Of The CEO | Leadership |
Hernan Cortez | Head, U.s. Key Accounts, Gastroenterology And Hepatology | Leadership |
Sara Whipple | Vice President - Financial Planning & Analysis | Leadership |
Doug Houser | Director, Strategic Accounts | Leadership |
Julia Pronina | Director, Financial Planning & Analysis | Leadership |
Thomas Rosenberg | Senior Director Accounting - Controller | Leadership |
Scott Kline | Head Of Benefits, Wellness, & Engagement | Leadership |
Sharon O. Ferrer | Senior Director, US Patient Services & Channel Operations | Leadership |
169 more people are available in the full profile.
Complete people profiles for Intercept Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Intercept Pharmaceuticals
5 dated milestones of Intercept Pharmaceuticals across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Intercept Pharmaceuticals is founded.
- Funding First funding round of $41.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $500.0M.
- Exit Acquired by Alfasigma.
Competitors of Intercept Pharmaceuticals
Intercept Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. |
Detailed competitors of Intercept Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Intercept Pharmaceuticals
The website of Intercept Pharmaceuticals (interceptpharma.com) receives about 7.7K visits a month and ranks #2,460,968 among all websites worldwide, #3,376 in Biotechnology and Pharmaceuticals.
- Monthly visits7.7K
▼ 12.4% vs previous month
- Unique visitors4K
per month
- Global rank#2,460,968
among all websites
- Category rank#3,376
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.8
- Average visit21 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Intercept Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| conatuspharma.com | 100% | 1K | #14,248,892 | View details | |
| agios.com | 100% | 21.8K | #1,284,134 | View details | |
| genfit.com | 94% | 4.9K | #3,666,893 | View details | |
| merck.com | 94% | 656.8K | #78,842 | View details | |
| fiercebiotech.com | 75% | 858.3K | #81,022 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Intercept Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Intercept Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intercept Pharmaceuticals
Complete news archive for Intercept Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intercept Pharmaceuticals
Intercept Pharmaceuticals was founded in 2002 and raised its 1st funding round 4 years after it was founded.
Intercept Pharmaceuticals is headquartered in New York, United States. It is registered at New York, New York, United States.
Intercept Pharmaceuticals is a funded company, having raised a total of $121M across 5 funding rounds to date. The company's 1st funding round was a Series A of $41M, raised on May 2006.
Intercept Pharmaceuticals has 341 employees.
Annual revenue of Intercept Pharmaceuticals is $285.71M as on Dec 31, 2022.
Developer of therapeutics to treat progressive non-viral liver diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic liver diseases such as Nonalcoholic steatohepatitis (NASH), and Primary sclerosing cholangitis. FXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue. FXR regulates a wide variety of target genes critically involved in the control of BA synthesis and transport, Lipid metabolism, and Glucose homeostasis.
Intercept Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.
Intercept Pharmaceuticals offers FXR Agonist.
Intercept Pharmaceuticals has 5 investors. Key investors include Orbimed, Alfasigma, Genextra, Balyasny Asset Management, and JAFCO Group.
Intercept Pharmaceuticals operates through Intercept Pharmaceuticals, Inc..
Yes. Intercept Pharmaceuticals was acquired by Alfasigma in September 2023.

